Therapeutic drug monitoring

MSU Health Care to Expand Services with In-House Laboratory

Retrieved on: 
Tuesday, August 8, 2023
MSU, Therapeutic drug monitoring, EMR, Teaching, Diagnosis, Research, Doctor of Philosophy, Patient, Blood, EAST, Toxicology, Health, Nursing, Medical device

EAST LANSING, Mich., Aug. 8, 2023 /PRNewswire/ -- MSU Health Care Laboratories, a joint venture between MSU Health Care and Grand Rapids-based private equity firm Auxo Investment Partners, has announced that operations of the laboratory will begin in mid-August.

Key Points: 
  • EAST LANSING, Mich., Aug. 8, 2023 /PRNewswire/ -- MSU Health Care Laboratories, a joint venture between MSU Health Care and Grand Rapids-based private equity firm Auxo Investment Partners, has announced that operations of the laboratory will begin in mid-August.
  • "Diagnostic testing is crucial for patient care," said Roger Jansen, PhD, MSU Health Care chief strategic growth officer.
  • "This laboratory will allow MSU Health Care to prioritize routine and specialized tests, ensuring comprehensive care for our communities.
  • MSU Health Care Laboratories, formed in 2022, strives to create a better laboratory experience for Michigan.

PrecisePK Establishes a New Standard of Care in Spain with Hospital Universitari Mutua Terrassa

Retrieved on: 
Thursday, June 15, 2023
Partnership, Doctor of Pharmacy, Therapeutic drug monitoring, Pharmacokinetics, Research, Pharmacist, Hospital, Vancomycin, SAN, AUC, Medicine, Patient, Health, TDM, Software, Nursing, Medical imaging

PrecisePK and Hospital Universitari Mutua Terrassa advance clinical pharmacokinetics in Spain with Bayesian dosing.

Key Points: 
  • PrecisePK and Hospital Universitari Mutua Terrassa advance clinical pharmacokinetics in Spain with Bayesian dosing.
  • Genís Castells, PharmD, an experienced hospital pharmacist leading TDM at Hospital Universitari Mutua Terrassa, expressed his satisfaction with the partnership.
  • "We are delighted to partner with Hospital Universitari Mutua Terrassa and contribute to their mission of delivering exceptional patient care," says Katherine Ninh, Operations and Accounts Manager at PrecisePK.
  • The collaboration between PrecisePK and Hospital Universitari Mutua Terrassa exemplifies the country's commitment to advancing the field of precision medicine and sets a precedent for other healthcare institutions to follow.

Lifespin Announces the Launch of its First Commercial Product in Regulated Healthcare

Retrieved on: 
Monday, May 22, 2023
Software as a service, Obesity, Therapeutic drug monitoring, Diabetes, Health status of Asian Americans, Dicarboxylic acid, Science, Metabolism, Patient, Physician, Algorithm, Amino acid, Health, Medical device

REGENSBURG, Germany, May 22, 2023 /PRNewswire/ -- Lifespin GmbH, a start-up medical diagnostics company with offices in Regensburg (Germany) and Boston (MA), announced today that it has launched Lifespin™ Amino Acid Profiler (LAAP) - its first commercial product for use in the regulated diagnostics field. Utilizing its proprietary AI-driven technology, Lifespin LAAP analyzes variations in patients' metabolism to provide clinicians with deep insights into patients' health and wellbeing.

Key Points: 
  • REGENSBURG, Germany, May 22, 2023 /PRNewswire/ -- Lifespin GmbH, a start-up medical diagnostics company with offices in Regensburg (Germany) and Boston (MA), announced today that it has launched Lifespin™ Amino Acid Profiler (LAAP) - its first commercial product for use in the regulated diagnostics field.
  • Utilizing its proprietary AI-driven technology, Lifespin LAAP analyzes variations in patients' metabolism to provide clinicians with deep insights into patients' health and wellbeing.
  • Amino acids have been shown to play a fundamental role in maintaining and controlling the normal physiological processes of the human body.
  • Analysis of the samples will be implemented by Lifespin at its sites in Germany and the US, utilizing its advanced and proprietary testing algorithms, and delivered to laboratory chain companies and healthcare providers as a Software-as-a-Service (SaaS).

Parkway Clinical Laboratories Launches Xylazine Testing

Retrieved on: 
Monday, May 8, 2023
Xylazine, Therapeutic drug monitoring, Naloxone, Urine, CAP, Multimedia, Heroin, PCL, DEA, EIA, Pain management, Fentanyl, Saliva, Substance abuse, Pharmaceutical industry

PHILADELPHIA, May 8, 2023 /PRNewswire/ -- Parkway Clinical Laboratories Inc. (PCL), today announced it has launched Xylazine aka "Tranq" testing via LCMSMS confirmation testing on urine specimens.

Key Points: 
  • PHILADELPHIA, May 8, 2023 /PRNewswire/ -- Parkway Clinical Laboratories Inc. (PCL), today announced it has launched Xylazine aka "Tranq" testing via LCMSMS confirmation testing on urine specimens.
  • This test is well suited for the purpose of addiction screening and opioid prescription drug monitoring and can help identify past or recent usage of xylazine.
  • Xylazine may result in life threatening side effects that appear to be similar to those commonly associated with opioid use, making it difficult to distinguish opioid overdoses from xylazine exposure.
  • Parkway Clinical Laboratories (PCL) is a College of American Pathologists (CAP) accredited, CLIA-certified, full service, specialty reference laboratory.

Health Canada should be transparent about how it's monitoring drug safety

Retrieved on: 
Thursday, May 4, 2023
REMS, Depression, Probability, Therapeutic drug monitoring, Data, Marketing, Registry, Disability, Group, COVID-19, Woman, Prescription, Research, Goal, Sale, RMP, Risk Evaluation and Mitigation Strategies, Name, Pharmacist, Food and Drug Administration Amendments Act of 2007, COVID-19 vaccine, Patient, Risk, Effectiveness, Diagnosis, Health, Health Canada, Environment, Food, Safety, Disease, REM, Medical device, Pharmaceutical industry, Dietary supplement, Risk management

Regulatory bodies like Health Canada are intended to ensure that approved drugs go through a rigorous multi-stage process.

Key Points: 
  • Regulatory bodies like Health Canada are intended to ensure that approved drugs go through a rigorous multi-stage process.
  • Once new drugs are approved for marketing in Canada, Health Canada continues to monitor them.

Clinical trials

    • Potential new drugs are assessed in clinical trials before they can be authorized for sale in Canada.
    • In addition, clinical trials often leave out children, the elderly, women, minority groups, people with disabilities and multiple other groups.
    • Usually only 3,000 to 5,000 people are exposed to an experimental drug in clinical trials.

Drug safety programs

    • That’s why when regulatory agencies like Health Canada approve a drug, they require the drug company to monitor post-market safety.
    • These programs go by various names; in Canada and Europe they are Risk Management Plans (RMP) and in the United States they are Risk Evaluation and Mitigation Strategies (REM).
    • Under these plans companies may have to conduct additional safety studies, set up registries to identify patients who are taking the drug, develop educational materials for health care professionals and/or patients, restrict access to the drug and commit to undertaking a number of other measures.

Access to drug monitoring information

    • In the U.S., people can turn to a Food and Drug Administration website that lists all the drugs with REMS.
    • Click on a hyperlink and it takes you to a summary of the RMP for the drug in question.
    • Two of Health Canada’s stated goals in implementing a system of RMPs are to “support Canadians’ timely access to safe, efficacious and high quality drugs and support ongoing evaluation of information that could have an impact on the benefit-risk profile of health products.” But without access to current information on specific drugs, Canadians cannot assess those risks for themselves, nor can they evaluate the monitoring program.
    • But Health Canada does not need to wait until then to make this information available to Canadians.

Lifespin Announces Inaugural Membership in the Industrial Participant Program of the Wyss Diagnostics Accelerator at Harvard University

Retrieved on: 
Thursday, April 20, 2023
Software, Research, General Health, Mobile, Wireless, Data Management, Apps, Applications, Technology, Medical Devices, Artificial Intelligence, Health Technology, Science, Health, Other Science, Yale University, Software as a service, CT, Obesity, Therapeutic drug monitoring, Diabetes, Engineering, NMR, Cone Health Women's Hospital, Inflammation, Metabolomics, DSM-IV codes, A.I, Risk, Biomarker, Harvard University, Metabolome, Wyss Institute for Biologically Inspired Engineering, IPP, RUO, Cell biology, Metabolism, Pathology, Patient, Wyss Institute, Cancer, Artificial intelligence, Hospital, Wyss, Neurology, Disease, Medical device, Medical imaging

Lifespin GmbH, based in Regensburg with offices in Boston, Massachusetts, announced today that it is one of 24 inaugural members of the Wyss Institute for Biologically Inspired Engineering at Harvard University’s Diagnostics Accelerator ( Wyss DxA ) Industrial Participant Program (IPP).

Key Points: 
  • Lifespin GmbH, based in Regensburg with offices in Boston, Massachusetts, announced today that it is one of 24 inaugural members of the Wyss Institute for Biologically Inspired Engineering at Harvard University’s Diagnostics Accelerator ( Wyss DxA ) Industrial Participant Program (IPP).
  • Originally formed in 2021 as a pilot program, the IPP recently has transitioned from its pilot phase into an official program within the Harvard system, and consolidated its base of initial industrial partners, including Lifespin.
  • “The mission of the Wyss DxA is to get transformative diagnostic tests to market and reduce disease burden for patients with major unmet needs.
  • Lifespin ( www.lifespin.health ) is a deep data company that seeks to detect distinct deviations in the human metabolism caused by diseases.

QIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023

Retrieved on: 
Friday, April 14, 2023
DNA, QIAGEN, QGEN, AACR, University, Therapeutic drug monitoring, Senior, Workflow, Nucleic acid thermodynamics, NGS, Liquid biopsy, Cancer, American Association for Cancer Research, Mutation, RNA, VAF, Chemistry, Patient, Blood, Central business district, Diagnosis, Fluid mechanics, Library, Gene, NYSE, PCR, Vaccine, Medical imaging

It will be one of the central features of QIAGEN’s life-science offering at the 2023 annual meeting of the American Association for Cancer Research (AACR) in Orlando, Florida, from April 14 to 19, 2023.

Key Points: 
  • It will be one of the central features of QIAGEN’s life-science offering at the 2023 annual meeting of the American Association for Cancer Research (AACR) in Orlando, Florida, from April 14 to 19, 2023.
  • Liquid biopsy centered on cfDNA has become a vital tool in the diagnosis, outcome prognosis and treatment monitoring of cancer and other diseases.
  • “QIAGEN is dedicated to driving innovation in liquid biopsy technology to enhance cancer research and improve patient outcomes.
  • QIAGEN is looking forward to hosting AACR attendees at booth #753 in Orlando’s Orange County Convention Center.

PrecisePK Expands Its Global Standing as The Most Trusted Bayesian Dosing Software for South Korea's Health Systems

Retrieved on: 
Monday, March 27, 2023
Tacrolimus, Kyung Hee University, Pharmacy, Therapeutic drug monitoring, Health, Bed, Infection, Pharmacokinetics, Research, Asan Medical Center, Acute kidney injury, Hospital, Vancomycin, Guideline, SAN, AUC, Busulfan, Medicine, Cardiology, Neurology, Health care, Pharmaceutical industry

SAN DIEGO, March 27, 2023 /PRNewswire/ -- Today, PrecisePK, an industry-trusted Bayesian Model-Informed Precision Dosing (MIPD) software, reports its technology is being implemented in many of South Korea's largest health systems.

Key Points: 
  • SAN DIEGO, March 27, 2023 /PRNewswire/ -- Today, PrecisePK, an industry-trusted Bayesian Model-Informed Precision Dosing (MIPD) software, reports its technology is being implemented in many of South Korea's largest health systems.
  • PrecisePK proudly offers drug models for more than 20 medications, including vancomycin, busulfan, tacrolimus, and many others, effectively delivering precision dosing to around 6,000 beds across these hospitals.
  • PrecisePK spearheads the worldwide application of Bayesian MIPD, trusted by additional major South Korean hospitals.
  • PrecisePK aims to enhance patient care by providing cutting-edge technology and empowering global healthcare professionals to ensure medication safety at international standards.

iCoreConnect, Inc. Expands Into Nebraska With Nebraska Dental Association Endorsement of iCoreRx ePrescription Software

Retrieved on: 
Tuesday, March 7, 2023
EPCS, Therapeutic drug monitoring, Software as a service, OTCQB, NDA, Practice management, Ground substance, Health, Pharmaceutical industry

OCOEE, FL, March 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – iCoreConnect, Inc., (OTCQB: ICCT), a cloud-based Software-as-a-Service (SaaS) enterprise and healthcare workflow platform, today announced  the Nebraska Dental Association’s (NDA) endorsement of iCoreConnect’s cloud-based ePrescription software, iCoreRx.

Key Points: 
  • OCOEE, FL, March 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – iCoreConnect, Inc., (OTCQB: ICCT), a cloud-based Software-as-a-Service (SaaS) enterprise and healthcare workflow platform, today announced  the Nebraska Dental Association’s (NDA) endorsement of iCoreConnect’s cloud-based ePrescription software, iCoreRx.
  • iCoreRx, in combination with its powerful add-on feature to electronically prescribe controlled substances (EPCS), boasts more than 40 endorsement agreements by state dental and medical associations.
  • Nebraska, and states across the country, are impacted by laws requiring ePrescribing for medications, including controlled substances.
  • iCoreConnect President and CEO Robert McDermott elaborates, “We knew early-on the impact these laws would have on the dental industry.

ELISA Analyzers Market to be Worth $754.38 Million by 2030: Grand View Research, Inc.

Retrieved on: 
Thursday, March 9, 2023
SAN, Incidence, Application, Workflow, Hormone, Research, ChromeOS, Growth, Biotechnology, Optics, USD, Antibody, Infection, Cardiology, Data analysis, Revenue, ELISA, Therapeutic drug monitoring, Endocrinology, Mode, Vaccine, Medical device, Fine chemical, Telecommunications

By Mode, automated analyzers is expected to capture the largest share of the market in 2022.

Key Points: 
  • By Mode, automated analyzers is expected to capture the largest share of the market in 2022.
  • The increasing incidence of chronic & infectious diseases is encouraging companies to enter the regional ELISA analyzers market.
  • Read 180-page market research report, " ELISA Analyzers Market Size, Share & Trends Analysis Report By Type (Optical Filter Elisa Analyzer, Optical Grating ELISA Analyzers), By Mode, By Application, By End-user, By Region, And Segment Forecasts, 2023 - 2030 ", published by Grand View Research.
  • Continuous technological advancements and the introduction of new products have also contributed to the ELISA analyzers market growth.